Most Popular
-
6
[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
-
7
North Korea removes streetlights along cross-border roads with South
-
8
Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
-
9
Farming households dip below 1m for first time in 2023
-
10
S. Korea votes in favor of Palestinian bid for UN membership
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
Korea OKs export of botulinum toxin developed by Huons Global
By 박한나Published : Oct. 11, 2016 - 17:41
[THE INVESTOR] South Korean pharmaceutical company Huons Global has been granted approval from the health authorities to export its botulinum toxin, the firm said on Oct. 11.
The move came after the Huons’ newly developed drug HU-014JU, which is designed to help smooth out forehead frown lines, got the green light from the Ministry of Food and Drug Safety for its first and second clinical trials in August.
“The product is set to enter the domestic market in 2018. We will push ahead with plans to get global approvals,” said Kim Wan-seop, senior executive at Huons Global.
The drug maker will also move forward with the treatment to win approval from the US Food and Drug Administration for its clinical trials next year.
Shares in the KOSDAQ-listed firm climbed 7.47 percent to close at 48,200 won.
By Park Han-na (hnpark@heraldcorp.com)
The move came after the Huons’ newly developed drug HU-014JU, which is designed to help smooth out forehead frown lines, got the green light from the Ministry of Food and Drug Safety for its first and second clinical trials in August.
“The product is set to enter the domestic market in 2018. We will push ahead with plans to get global approvals,” said Kim Wan-seop, senior executive at Huons Global.
The drug maker will also move forward with the treatment to win approval from the US Food and Drug Administration for its clinical trials next year.
Shares in the KOSDAQ-listed firm climbed 7.47 percent to close at 48,200 won.
By Park Han-na (hnpark@heraldcorp.com)
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
![[Today’s K-pop] Illit drops debut single remix](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/19/20240419050612_0.jpg&u=)